Start-up Erasca has launched with $1.7 billion of series A funding. The San Diego-based pharmaceutical company said it aims to concentrate initially on small-molecule drugs for the treatment of solid tumours. It describes its goal as not just treating cancer, but eradicating residual disease, using numerous therapeutic modalities, including combination therapies.
Start-up Erasca has launched with $42m of series A funding. The San Diego-based pharmaceutical company said it aims to concentrate initially on small-molecule drugs for the treatment of solid tumours. It describes its goal as not just treating cancer, but eradicating residual disease, using numerous therapeutic modalities, including combination therapies.